ELOA

Across TCGA pan-cancer cohorts, ELOA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELOA data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ELOA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELOA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and PCPG are the cancer types where ELOA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.143	0.638	<.001	18	view →
UCEC	DFS	Median	All	0.961	0.625	.016	8	view →
PCPG	DFS	Median	All	0.088	0.768	.002	6	view →
PRAD	DFS	Median	All	0.052	0.935	<.001	6	view →
LIHC	DFS	Median	All	0.185	0.545	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELOA–STAD (OS)

Open the STAD breakdown →